Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Friday, ThisIsMoney.Co.Uk reports.
A number of other equities research analysts have also recently issued reports on the company. Jefferies Financial Group reiterated a buy rating and issued a C$15.00 target price on shares of Aphria in a research note on Friday, May 24th. Credit Suisse Group reiterated a sell rating and issued a $6.50 target price on shares of Deutsche Bank in a research note on Monday, April 29th. Goldman Sachs Group cut EXPERIAN PLC/ADR from a buy rating to a neutral rating in a research note on Wednesday, July 10th. UBS Group upgraded to a neutral rating and raised their target price for the company from GBX 945 ($12.35) to GBX 2,060 ($26.92) in a research note on Thursday, June 20th. Finally, Morgan Stanley raised their target price on SYSCO from $69.00 to $72.00 and gave the company an equal weight rating in a research note on Tuesday, May 7th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of Hold and an average target price of GBX 6,502.94 ($84.97).
AZN stock opened at GBX 6,331 ($82.73) on Friday. The company has a debt-to-equity ratio of 179.66, a current ratio of 0.75 and a quick ratio of 0.57. The company has a market capitalization of $83.05 billion and a PE ratio of 33.32. AstraZeneca has a 1 year low of GBX 5,312 ($69.41) and a 1 year high of GBX 6,634 ($86.68). The company has a fifty day moving average of GBX 6,262.20.
In related news, insider Philip A. J. Broadley acquired 520 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were acquired at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer acquired 8,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were bought at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.